Physician profile
John Blanzy
NPI 1629017207
$3,257.40
in general payments reported to CMS, 2019-2025
13 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2021: $154 · 2022: $434 · 2023: $782 · 2024: $803 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $491.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $473.47 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Ani Pharmaceuticals, INC. | $440.36 | 2023-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $429.67 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $418.88 | 2022-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $392.90 | 2019-2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $110.59 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $108.61 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $76.36 | 2021 | |
| Edwards Lifesciences Corporation | $70.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.58 | 2022 | |
| Amarin Pharma, INC. | $50.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Blanzy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.